Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
X4 Pharma Raises USD25.8 Million in Venture Financing 11
X4 Pharma Raises USD37.5 Million in Series A Financing Round 12
X4 Pharma Raises USD0.7 Million in Seed Financing Round 13
Partnerships 14
X4 Pharma Enters into Research Agreement with Yale University 14
Licensing Agreements 15
X4 Pharma Enters into Licensing Agreement with Sanofi 15
Equity Offering 16
X4 Pharma Spin Off from Sanofi 16
X4 Pharmaceuticals Inc – Key Competitors 17
X4 Pharmaceuticals Inc – Key Employees 18
X4 Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Nov 05, 2018: X4 Pharmaceuticals appoints Gary J. Bridger, PhD, to board of directors 20
Jul 12, 2018: X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors 21
Jan 23, 2017: X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer 22
Product News 23
11/16/2017: First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting 23
10/30/2017: Clinical Data for X4P-001-IO in Combination with Inlyta (Axitinib) Demonstrated Encouraging Overall Response Rates (Including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma 24
08/31/2017: First Data from Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the European Society of Medical Oncology 2017 Congress 25
05/25/2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 26
05/17/2018: X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM Syndrome 27
05/16/2018: X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma 28
05/08/2018: X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo (nivolumab) 29
04/16/2018: X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity 30
01/30/2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease 31
01/26/2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell 32
Clinical Trials 33
Mar 15, 2018: X4 Pharmaceuticals to Report Clinical Biomarker Data with X4P-001 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting 33
Dec 11, 2017: First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients with WHIM Syndrome, a Primary Immunodeficiency Disease 34
Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO 35
Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting 36
Oct 25, 2017: Updated Clinical Data from Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 37
Sep 11, 2017: Initial Clinical Trial Data for Combination of X4P-001-IO and Inlyta® (Axitinib) Demonstrate Encouraging Disease Control Rates and Durable Clinical Responses in Patients with Clear Cell Renal Cell Carcinoma 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
X4 Pharma Raises USD25.8 Million in Venture Financing 11
X4 Pharma Raises USD37.5 Million in Series A Financing Round 12
X4 Pharma Raises USD0.7 Million in Seed Financing Round 13
X4 Pharma Enters into Research Agreement with Yale University 14
X4 Pharma Enters into Licensing Agreement with Sanofi 15
X4 Pharma Spin Off from Sanofi 16
X4 Pharmaceuticals Inc, Key Competitors 17
X4 Pharmaceuticals Inc, Key Employees 18
List of Figures
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9